{"@id":"https://bioecon.ru/technology/targeted-degradation-of-circulating-proteins/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/targeted-degradation-of-circulating-proteins/","json":"https://cn.bioecon.ru/api/v1/technology/targeted-degradation-of-circulating-proteins/index.json"},"id":"targeted-degradation-of-circulating-proteins","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/iita/","https://bioecon.ru/companies/21st-bio/","https://bioecon.ru/companies/icipe/","https://bioecon.ru/companies/abis-foods-and-proteins-private-limited/","https://bioecon.ru/companies/amai-proteins/","https://bioecon.ru/companies/cimv/","https://bioecon.ru/companies/european-protein-as/"]},"maturity":7,"name":"循环血液致病蛋白靶向溶酶体降解技术","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"肝细胞表面受体结合配体分子合成"},{"n":2,"title":"致病性血浆循环大分子特异性捕获偶联"},{"n":3,"title":"微流控肝细胞内吞与溶酶体降解追踪"},{"n":4,"title":"体内循环致病蛋白长效持久清除确证"}],"summary":"通过双功能双特异性分子（如LYTAC与GalNAc共轭嵌合体），一端特异性结合血浆循环中的致病性大分子或自身抗体，另一端高亲和力结合肝细胞清除受体（ASGPR/CI-M6PR），介导内吞并彻底于溶酶体降解。","url":"/technology/targeted-degradation-of-circulating-proteins/","verified":"2026-11-22"}